| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
NMDA (N-Methyl-D-aspartic acid; LC488A; LC488 A; LC488-A; LC 488A; LC-488A) is an aspartic acid analog with an N-methyl substituent and D-configuration and a glutamate-like excitatory chemical substance. It acts as a potent and specific agonist for NMDA receptor mimicking the action of glutamate, which is a neurotransmitter acting at NMDA receptors.
| ln Vitro |
Regardless of the incubation temperature, NMDA dramatically increases adrenal binding in a concentration-dependent manner [2].
|
||
|---|---|---|---|
| ln Vivo |
NMDA (0.2 nM) had a substantial effect on MF, IF, IL, and EL, reducing installation and insertion frequency while shortening insertion and ejaculation times. During the 30-minute mating test, NMDA and AP-5 significantly increased and decreased ejaculation behavior, respectively. Bilateral microinjection of NMDA into the PVN significantly raised baseline LSNA, with the greatest rise happening within 5 minutes [1].
|
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
N-methyl-D-aspartic acid is an aspartic acid derivative having an N-methyl substituent and D-configuration. It has a role as a neurotransmitter agent. It is a D-alpha-amino acid, a D-aspartic acid derivative, an amino dicarboxylic acid and a secondary amino compound.
An amino acid that, as the D-isomer, is the defining agonist for the NMDA receptor subtype of glutamate receptors (RECEPTORS, NMDA). |
| Molecular Formula |
C5H9NO4
|
|
|---|---|---|
| Molecular Weight |
147.13
|
|
| Exact Mass |
147.053
|
|
| CAS # |
6384-92-5
|
|
| Related CAS # |
|
|
| PubChem CID |
22880
|
|
| Appearance |
White to off-white solid powder
|
|
| Density |
1.3±0.1 g/cm3
|
|
| Boiling Point |
258.2±30.0 °C at 760 mmHg
|
|
| Melting Point |
187-192 °C
|
|
| Flash Point |
110.0±24.6 °C
|
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
|
| Index of Refraction |
1.494
|
|
| LogP |
-0.44
|
|
| Hydrogen Bond Donor Count |
3
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
4
|
|
| Heavy Atom Count |
10
|
|
| Complexity |
145
|
|
| Defined Atom Stereocenter Count |
1
|
|
| SMILES |
CN[C@H](CC(=O)O)C(=O)O
|
|
| InChi Key |
HOKKHZGPKSLGJE-GSVOUGTGSA-N
|
|
| InChi Code |
InChI=1S/C5H9NO4/c1-6-3(5(9)10)2-4(7)8/h3,6H,2H2,1H3,(H,7,8)(H,9,10)/t3-/m1/s1
|
|
| Chemical Name |
(2R)-2-(methylamino)butanedioic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (6.80 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (6.80 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (6.80 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 36.67 mg/mL (249.24 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7967 mL | 33.9836 mL | 67.9671 mL | |
| 5 mM | 1.3593 mL | 6.7967 mL | 13.5934 mL | |
| 10 mM | 0.6797 mL | 3.3984 mL | 6.7967 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06183788 | Recruiting | Behavioral: Remote cognitive rehabilitation program |
Anti-NMDA Receptor Encephalitis | Fundacion Clinic per a la Recerca Biomédica | January 16, 2023 | Not Applicable |
| NCT05977023 | Recruiting | Drug: NMDAE Drug: Placebo Cap |
Bipolar I Disorder | China Medical University Hospital | October 4, 2023 | Phase 2 |
| NCT05136755 | Recruiting | Drug: NMDAE Drug: Placebo Cap |
Major Depressive Disorder | China Medical University Hospital | January 25, 2022 | Phase 2 |
| NCT04745143 | Recruiting | Drug: NMDAE Drug: Placebo Cap |
Schizophrenia | China Medical University Hospital | January 1, 2018 | Phase 2 |
| NCT02950233 | Terminated | Drug: NMDA active Drug: Steroid active Drug: NMDA placebo Drug: Steroid placebo |
Pain, Postoperative | Population Health Research Institute | May 4, 2017 | Phase 3 |
|
|---|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
